Targeting KRAS Mutations: A Novel Approach in Advanced NSCLC

Targeting KRAS Mutations: A Novel Approach in Advanced NSCLC

Episodes

Specialty:

All

Year:

All

EP. 1: Current Management of Oncogene-Driven NSCLC

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

EP. 2: KRAS Mutations in Solid Tumors

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

EP. 3: Testing for KRAS Mutations in NSCLC

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

EP. 4: Counseling Patients With NSCLC When KRAS is Detected

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

EP. 5: Systemic Therapy for KRAS+ Advanced NSCLC

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

EP. 6: Development of KRAS G12C-Targeted Therapy in NSCLC

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

EP. 7: KRAS G12C Inhibition in Advanced NSCLC: AMG 510

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

EP. 8: KRAS G12C Inhibition in Advanced NSCLC: MRTX849

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

Trending on OncLive

FDA Grants Breakthrough Therapy Designation to JBS-003 for Radiation De-Escalation in HPV+ Oropharyngeal Cancer

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC

Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma

A New Player in the Adjuvant Setting? GLP-1 Agonists and the Fight Against Breast Cancer Metastasis

Novel Therapies Are Poised to Answer Questions and Reinvigorate Hematologic Oncology at SOHO 2026